Search...
/
The Fly Cast
Press play to listen
Smarter market moves start here
Over a week ago
Jun 5, 7:06 AM
Jun 3, 12:51 PM
Jun 3, 12:01 PM
Jun 2, 9:32 AM
Jun 1, 6:23 AM
Jun 1, 6:22 AM
Jun 1, 6:21 AM
May 14, 4:18 PM
May 14, 4:18 PM
Apr 17, 4:05 PM
Feb 25, 7:11 AM
Jan 28, 6:11 AM
Jan 27, 7:10 AM
Jan 27, 7:08 AM
Jan 5, 8:56 AM
Nov 6, 6:02 PM
Nov 6, 5:59 PM
Aug 6, 6:16 AM
Competitive Advantages
Novel Mechanism of Action: Onvansertib targets PLK1, a key enzyme involved in cell division, representing a unique approach to cancer therapy that may overcome resistance to existing treatments.
Synergistic Combination Strategy: The company's focus on combining onvansertib with standard-of-care therapies aims to enhance efficacy and improve patient outcomes by leveraging established treatments, rather than replacing them.
Promising Clinical Efficacy Signals: Early-phase clinical trial results have shown encouraging activity and disease control rates in difficult-to-treat patient populations, particularly in KRAS-mutated metastatic colorectal cancer (mCRC) and relapsed/refractory acute myeloid leukemia (AML).
Risks
Clinical Trial Failure Risk: Clinical trials for Onvansertib or any future product candidates may not demonstrate sufficient efficacy or safety to warrant further development or regulatory approval.
Regulatory Approval Risk: Even if clinical trials are successful, Onvansertib may not receive necessary regulatory approvals from health authorities like the FDA, which would prevent its commercialization.
Funding and Liquidity Risk: Cardiff Oncology is a clinical-stage company with no revenue-generating products and will require substantial additional financing to complete development and commercialization, which may not be available on favorable terms or at all.